中国现代医学杂志2026，Vol.36Issue(11)：24-30,7.DOI:10.3969/j.issn.1005-8982.2026.11.004
钠-葡萄糖协同转运蛋白2抑制剂联合金匮肾气丸对Ⅲ、Ⅳ期糖尿病肾病的应用效果研究
Study on the efficacy of SGLT-2 inhibitors combined with Jinkui Shenqi Pill in patients with stage Ⅲ-Ⅳ diabetic kidney disease
摘要
Abstract
Objective To evaluate the effects and safety of adding Jinkui Shenqi Pill to standard hypoglycemic and renal protection regimens on renal function,oxidative-inflammatory status,and quality of life in patients with stage Ⅲ-Ⅳ diabetic kidney disease(DKD).Methods A total of 126 patients with stage Ⅲ-Ⅳ DKD treated in Longnan Hospital of Daqing from February 2022 to February 2025 were retrospectively enrolled.All patients received routine standard hypoglycemic treatment.The control group(63 cases)received sodium-glucose cotransporter 2 inhibitors(SGLT-2I),and the observation group(63 cases)received additional Jinkui Shenqi Pill on the basis of the control group.The estimated glomerular filtration rate(eGFR),urine albumin-creatinine ratio(UACR),24-hour urinary albumin excretion rate(AER),glomerular-tubular function indexes(urine total protein/creatinine ratio,kidney injury molecule-1[KIM-1],neutrophil gelatinase-associated lipocalin[NGAL],N-acetyl-β-D-glucosaminidase[NAG]),oxidative stress indicators(superoxide dismutase[SOD],glutathione peroxidase[GSH-Px],malondialdehyde[MDA]),Kidney Disease Quality of Life(KDQOL-36)scores,glycemic indicators(glycated hemoglobin[HbA1c],fasting plasma glucose[FPG]),and adverse events were compared between the two groups before and after treatment.Results After 8 weeks of treatment,the observation group had higher eGFR,and lower UACR and 24h AER than the control group(P<0.05).Urine total protein/creatinine ratio,urinary KIM-1,NGAL and NAG were lower in the observation group(P<0.05).SOD and GSH-Px were higher,while plasma MDA and urinary MDA were lower in the observation group(P<0.05).The pre-to-post-treatment reductions in HbA1c and FPG were greater in the observation group than in the control group(P<0.05).All dimensions of KDQOL-36 scores were higher in the observation group(P<0.05).The total incidence of adverse events was lower in the observation group(P<0.05).Conclusion Combining Jinkui Shenqi Pill with SGLT-2 inhibitors significantly slows renal function decline,reduces proteinuria and tubular injury,improves oxidative-inflammatory status and quality of life,and lowers overall adverse events in stage Ⅲ-Ⅳ DKD patients.关键词
糖尿病肾病/钠-葡萄糖协同转运蛋白2抑制剂/金匮肾气丸/肾功能/不良反应Key words
diabetic kidney disease/SGLT-2 inhibitors/Jinkui Shenqi Pill/renal function/adverse reactions分类
医药卫生引用本文复制引用
贾晶,孙美娜..钠-葡萄糖协同转运蛋白2抑制剂联合金匮肾气丸对Ⅲ、Ⅳ期糖尿病肾病的应用效果研究[J].中国现代医学杂志,2026,36(11):24-30,7.基金项目
黑龙江省自然科学计划项目(2024XE0269) （2024XE0269）
